Inactive Instrument

Cell MedX Corp Stock OTC Bulletin Board

Equities

US15115X1072

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board
- USD - Intraday chart for Cell MedX Corp
Sales 2022 0.01 Sales 2023 0 Capitalization 6.29K
Net income 2022 - Net income 2023 - EV / Sales 2022 1,135,153,669 x
Net Debt 2022 592K Net Debt 2023 903K EV / Sales 2023 329,116,944 x
P/E ratio 2022
-9.01 x
P/E ratio 2023
-0.01 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 20.34%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 54 Dec. 11
Director of Finance/CFO 45 14-11-23
Chairman 76 18-03-22
Members of the board TitleAgeSince
Chief Executive Officer 54 Dec. 11
Director/Board Member 63 22-04-26
Director/Board Member 59 20-06-07
More insiders
Cell MedX Corp. is a biotechnology company. It is focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, general health, pain relief, wellness and alleviate complications associated with medical conditions including, diabetes, Parkinson’s disease, high blood pressure, neuropathy, and kidney function. The Company, through its subsidiary, is engaged in developing and manufacturing therapeutic devices based on its eBalance technology, which harnesses the power of microcurrents and its effects on the human body. The eBalance Pro System and eBalance Home System, are microcurrent electrotherapy systems intended to administer a specific variety of therapeutic microcurrent algorithms for temporary relief of pain associated with sore/aching muscles in the shoulders, waist, back, neck, upper extremities (arms) and lower extremities. Its Microcurrent therapy uses molecular bioelectricity in cell-to-cell signaling.
More about the company